Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Register for an upcoming webcast
Please join Prescient Therapeutics CEO Steven Yatomi-Clarke for a special live investor briefing.
Event Details:
Register for an upcoming webcast
In the session, Steven will discuss:
- PTX’s three new next-gen CAR-T programs in hematological and solid cancers with massive addressable markets and unmet needs
- Using OmniCAR’s unique features to create therapies where current generation CAR-Ts have struggled
- Additional follow-on research programs will also demonstrate OmniCAR’s many unique features and properties and create future clinical candidates
This is a live and interactive session, you simply need an internet connection to participate. Don’t miss out, spots are limited – This is a FREE event.
Book Your Spot
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.
FEATURED SPEAKER
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.